HOME >> BIOLOGY >> NEWS
Research to create lung-cancer blood tests receives $3.4M in Pennsylvania tobacco settlement funds

(PHILADELPHIA Thursday, March 11, 2004) A team of researchers from The Wistar Institute, Fox Chase Cancer Center, and the University of Pennsylvania has been awarded $3.4 million to pursue development of blood tests for lung cancer. The need for such tests is great lung cancer kills more Americans by far than any other form of cancer, according to statistics compiled by the American Cancer Society.

As with most cancers, treatment for lung cancer is much more effective when the cancer is detected at an early stage. The Wistar-led research team will use a systems-biology approach primarily applying the recently developed tools of proteomics and genomics to find proteins and genes in the blood that indicate the presence of early lung cancer. They will then develop blood tests based on this information that could aid many people by detecting their cancers at an earlier stage than is currently possible.

"This funding allows us to bring together an expert team of basic scientists and clinicians to tackle a critical medical problem," said David W. Speicher, Ph.D., professor and co-leader of the molecular and cellular oncogenesis program at The Wistar Institute and principal investigator on the lung-cancer project. "Our aim is to develop powerful new diagnostic tools that should help save lives through earlier cancer detection."

The announcement of the grant was made today by Pennsylvania Health Secretary Dr. Calvin Johnson on behalf of Governor Edward G. Rendell. The grant was one of five health research grants totaling $22.5 million funded from Pennsylvania's share of the national tobacco settlement.

These non-formula grants competitive grants based on research priorities and not dictated by a formula will develop Centers of Excellence to reduce disparities in lung disease and pregnancy outcomes. "Center of Excellence" is a special designation given to medical or educational institutions conducting concentrated, s
'"/>

Contact: Franklin Hoke
hoke@wistar.upenn.edu
215-898-3716
The Wistar Institute
12-Mar-2004


Page: 1 2 3

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
4. Researchers identify protein promoting vascular tumor growth
5. Researchers devise potent new tools to curb ivory poaching
6. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
7. Researchers ID chlorophyll-regulating gene
8. Environmental issues center of Inland Northwest Research Alliance 4th Annual Symposium
9. Research suggests new avenue for stopping, preventing colon cancer
10. Researchers develop fast track way to discover how cells are regulated
11. Research on carbohydrate metabolism receives historical recognition

Post Your Comments:
(Date:5/20/2013)... - A novel vaccine study from South Dakota ... will be unveiled at the American Association of Pharmaceutical ... place Monday, May 20 - Wednesday, May 22 at ... "The main goal of a vaccine is to stimulate ... causes the disease", explained Dr. Hemachand Tummala, assistant professor ...
(Date:5/19/2013)... A novel study reports that white men and women ... bunions (hallux valgus) and lesser toe deformities, including hammer ... first to estimate the heritability of foot disorders in ... journal published by Wiley on behalf of the American ... that as many as 60% of older adults have ...
(Date:5/18/2013)... MD (May 19, 2013) The AGA Research Foundation ... and Damian Augustyn Award in Digestive Cancer, which will ... of Medicine at the University of Pennsylvania, Philadelphia, as ... in pancreas development, regeneration and cancer progression. , "The ... in honor of two distinguished clinicians and AGA Legacy ...
Breaking Biology News(10 mins):Germ-fighting vaccine system makes great strides in delivery 2Blame your parents for bunion woes 2AGA Research Foundation grant furthers digestive cancer research 2
(Date:5/20/2013)... Today, at the American Psychiatric Association (APA) ... James McGough , M.D., M.S., principal investigator ... for Neuroscience and Human Behavior and David ... of California Los Angeles (UCLA), and director of clinical ... ADHD at UCLA, presented the results of a Phase ...
(Date:5/20/2013)... Biomarkers and Clinigene International are set to unveil their ... 2013 AAPS/ National Biotechnology Conference May 20-22 ... Marina , San Diego, CA. ... company representatives at their collaborative seminar, "Biosimilarity, Immunogenicity and ... 1-2 p.m. in the conference,s Spinnaker Room. ...
(Date:5/20/2013)... , May 20, 2013 Cempra, Inc. ... developing differentiated antibiotics to meet critical medical needs ... that it presented data at the American Thoracic ... Philadelphia demonstrating the antibacterial and enhanced ... prior Phase 2 clinical trial in outpatients with ...
(Date:5/20/2013)... 2013 Interventional cardiologist Tony Farah, MD, ... (AGH) Cardiovascular Institute have helped pioneer many breakthroughs ... (CAD) over the past three decades, from new ... and coronary artery stent implantation. , Today, AGH officials ... prominent role in the study of a novel, first-of-its ...
Breaking Biology Technology:Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5Pacific Biomarkers and Clinigene International To Announce Laboratory Solutions for Developers of Biosimilars at 2013 AAPS/ National Biotechnology Conference 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4
Cached News: